Arcus Biosciences, Inc.
RCUS· NYSE
Released Aug 5, 2026, after the close
10-Q filed Aug 5, 2026, 36 days after period end · 0001724521-26-000044
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $33.00M | $8.00M | $11.00M | $29.00M |
| Net Income | -$91.00M | $0.00 | -$93.00M | -$75.00M |
| EPS Diluted |
Arcus Biosciences, Inc. · CIK 1724521 · Engraved from SEC EDGAR
| -$0.72 |
| $0.00 |
| -$1.02 |
| -$1.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.